RxDoctor Payments DataLook up a doctor →

Cleo Valdez

Primary Care · Huntsville, ALNPI 1831586098

Payments from drug & device makers

$13,638in general payments, 2019–2025

Across 415 payments — averaging $32.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sobi, Inc$3K
  • Merck$754
  • Karyopharm Therapeutics Inc.$746
  • Novartis$674
  • AstraZeneca$663
  • Mirati Therapeutics, Inc.$588
  • plus $7K from 53 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sobi, Inc9$2,909
Merck34$754
Karyopharm Therapeutics Inc.6$746
Novartis34$674
AstraZeneca(2 entities)27$663
Mirati Therapeutics, Inc.2$588
Johnson & Johnson24$572
Seagen Inc.17$504
Incyte Corporation14$468
Daiichi Sankyo Inc.13$438
Sanofi8$411
Pfizer19$356
Bristol Myers Squibb11$300
E.r. Squibb & Sons, L.L.C.18$299
Boehringer Ingelheim12$297
Janssen Scientific Affairs, LLC2$228
Takeda Pharmaceuticals U.S.A., Inc.8$209
AbbVie10$202
Beone Medicines USA, Inc.13$200
GSK8$186
Gilead(2 entities)9$185
Exelixis Inc.8$184
Eisai Inc.8$172
Blueprint Medicines Corporation6$161
Stemline Therapeutics Inc.5$141
Lilly USA, LLC9$140
Genentech USA, Inc.6$106
TG Therapeutics, Inc.1$105
Pharmacyclics LLC, An Abbvie Company6$103
Amgen6$100
Beigene USA, Inc.5$91
Array Biopharma Inc4$83
Jazz Pharmaceuticals Inc.3$83
Ipsen Biopharmaceuticals, Inc3$76
Puma Biotechnology, Inc.4$75
Bayer4$73
Regeneron Healthcare Solutions, Inc.4$71
Pharmaessentia USA Corporation2$60
Astellas Pharma US Inc3$59
Sumitomo Pharma America, Inc.3$56
Genmab U.S., Inc.2$56
Acrotech Biopharma Inc.3$51
AVEO Pharmaceuticals, Inc.2$36
Immunocore Limited1$36
Tersera Therapeutics LLC2$36
Agios Pharmaceuticals, Inc.2$33
Kyowa Kirin, Inc.2$32
Fresenius Kabi USA, LLC2$31
Deciphera Pharmaceuticals Inc.1$27
Myriad Genetic Laboratories, Inc.1$24
Iovance Biotherapeutics, Inc.1$23
Taiho Oncology, Inc.1$18
Myovant Sciences Inc.1$18
Mylan Institutional Inc.1$17
G1 Therapeutics, Inc.1$16
Morphosys, US Inc.1$15
ADC Therapeutics America, Inc.1$14
Clovis Oncology, Inc.1$14
Dova Pharmaceuticals1$13

How this compares

$13,638 in reported general payments places this provider in the 95th percentile of 159 primary care providers in Alabama.

See all primary care providers in Alabama

Medicare billing

Part B allowed, 2024
$25,437
Medicare patients
161
Services billed
292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other primary care in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →